Safety, pharmacokinetics, and pharmacodynamics of anti‐IL‐4Rα antibody SHR‐1819 in healthy subjects: A randomized, controlled phase I study
Abstract SHR‐1819 is a novel anti‐IL‐4Rα monoclonal antibody currently under clinical development for use in patients with type 2 inflammatory diseases. In this randomized, double‐blind, placebo‐controlled, single‐dose escalation phase I trial, we evaluated the safety, tolerability, pharmacokinetics...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | |
| Опубликовано: |
Wiley,
2024-04-01T00:00:00Z.
|
| Предметы: | |
| Online-ссылка: | Connect to this object online. |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Internet
Connect to this object online.3rd Floor Main Library
| Шифр: |
A1234.567 |
|---|---|
| Копировать 1 | Доступно |